Navigation Links
BioMarin to Host a Research and Development Day on December 8th
Date:11/17/2011

NOVATO, Calif., Nov. 17, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Thursday, December 8, 2011 from 8:00 a.m. to 12:00 p.m. at the Four Seasons Hotel in New York City.  Members of BioMarin's management team and industry experts will provide an update on the company's product portfolio and advancements in the research and development pipeline.Dial-in informationToll-free number: (877) 643-7155International number: (914) 495-8552Conference ID #: 28775391Replay informationToll-free number: (855) 859-2056International number: (404) 537-3406Conference ID #: 28775391Interested parties may access a live audio webcast and slides of the presentation via the investor section of the BioMarin website, http://www.BMRN.com.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease; and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Announces Third Quarter 2011 Financial Results
2. BioMarin to Present at the UBS Global Life Sciences Conference
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Baird Health Care Conference
5. BioMarin to Present at the Wedbush Life Sciences Conference
6. BioMarin Announces Second Quarter 2011 Financial Results
7. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
8. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
9. BioMarin to Present at the William Blair Growth Stock Conference
10. BioMarin to Present at the Jefferies Global Healthcare Conference
11. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Bill is an internationally experienced medical device industry executive who has ... medical device companies, including Smith & Nephew, Angiodynamics, Orthovita and Stryker. ... building successful businesses in the sector and has worked in ... North America . ... Educated at the University of Edinburgh (Dental Surgery), University ...
(Date:1/16/2017)... Tenn. , Jan. 16, 2017  Cumberland Pharmaceuticals ... of Kenneth J. Krogulski , CFA to its ... Executive Officer of Berkshire Asset Management LLC . ... a 30-year-old independent SEC registered investment advisory firm with ... has over 37 years, experience in security analysis and ...
(Date:1/15/2017)... 14, 2017 ImmersiveTouch Inc., the global leader ... announced recent appointments strengthening their Executive Management team.  ... as Chief Executive Officer, Jay Banerjee as ... President of Sales and Jia Luo , PhD ... Mr. Bowman has 20 years experience commercializing ...
Breaking Medicine Technology:
(Date:1/16/2017)... CA (PRWEB) , ... January 16, 2017 , ... ... manuscript in the Aesthetic Surgery Journal , the official journal of The ... conducted on lower eyelid retraction surgery. The procedure is designed to correct drooping, ...
(Date:1/16/2017)... ... , ... NexTec Group has been selected as a member of the Bob ... in the field of midmarket financial software. , Members of the VAR Stars were ... not based on revenue and those firms chosen represent a wide range of size ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music themed slideshow production ... said Christina Austin - CEO of Pixel Film Studios. , On Tour’s new ... style and animation of their slideshows. Place each slide on top of another slide ...
(Date:1/14/2017)... MN (PRWEB) , ... January 14, 2017 , ... ... present the distinctions among their expanding line of activated charcoal products. With more ... the importance of categorizing their products according to how they cater to specific ...
(Date:1/13/2017)... , ... January 13, 2017 , ... The 18th European ... America hotel on March 3-4, 2017. This Congress is expertly designed to meet ... management of patients with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor ...
Breaking Medicine News(10 mins):